28 unchanged sentences
We have audited ResMed Inc.
−Removed: and subsidiaries’ (the Company) internal control over financial reporting as of June 30, 2020, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
+Added: and subsidiaries'
+Added: (the Company) internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
15 unchanged sentences
and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
−Removed: AND SUBSIDIARIES
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
32 unchanged sentences
33-91094) declared effective on June 1, 1995)
−Removed: Description of ResMed Inc.’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934
−Removed: Licensing Agreement between the University of Sydney and ResMed Ltd dated May 17, 1991, as amended.
−Removed: (Incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1 (No.
−Removed: 33-91094) declared effective on June 1, 1995)
−Removed: 2006 Incentive Award Plan.
−Removed: (Incorporated by reference to Exhibit 99.1 to the Registrant’s Report on Form 8-K filed on November 15, 2006)
−Removed: Amendment No.
−Removed: 1 to the ResMed Inc.
−Removed: 2006 Incentive Award Plan.
−Removed: (Incorporated by reference to Exhibit 10.24 to the Registrant’s Report on Form 10-Q for the quarter ended December 31, 2006, filed on February 8, 2007)
−Removed: 2006 Grant agreement for Board of Directors.
−Removed: (Incorporated by reference to Exhibit 10.25 to the Registrant’s Report on Form 10-Q for the quarter ended December 31, 2006 filed on February 8, 2007)
−Removed: 2006 Grant agreement for Executive Officers.
−Removed: (Incorporated by reference to Exhibit 10.26 to the Registrant’s Report on Form 10-K for the year ended June 30, 2007, filed on August 28, 2007)
−Removed: 2006 Grant agreement for Australian Executive Officers.
−Removed: (Incorporated by reference to Exhibit 10.27 to the Registrant’s Report on Form 10-K for the year ended June 30, 2007, filed on August 28, 2007)
−Removed: Form of Executive Agreement.
−Removed: (Incorporated by reference to Exhibit 99.1 to the Registrant’s Report on Form 8-K filed on July 13, 2007)
−Removed: Amended and Restated 2006 Incentive Award Plan dated November 20, 2008.
−Removed: (Incorporated by reference to Appendix 1 of the Registrant’s Definitive Proxy Statement filed on October 15, 2008)
+Added: Description of ResMed Inc.’s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Report on Form 10-K filed on August 13, 2020)
Form of Indemnification Agreements for our directors and officers.
−Removed: (Incorporated by reference to Exhibit 10.1 the Registrant’s Report on Form 8-K filed on June 24, 2009)
+Added: (Incorporated by reference to Exhibit 10.1 to the Registrant’s Report on Form 8-K filed on June 24, 2009)
Form of Access Agreement for directors.
−Removed: (Incorporated by reference to Exhibit 10.2 the Registrant’s Report on Form 8-K filed on June 24, 2009)
+Added: (Incorporated by reference to Exhibit 10.2 to the Registrant’s Report on Form 8-K filed on June 24, 2009)
Updated Form of Executive Agreement.
3 unchanged sentences
(Incorporated by reference to Appendix B of ResMed Inc.’s Proxy Statement filed with the Securities and Exchange Commission on September 25, 2017)
−Removed: 2009 Incentive Award Plan .
−Removed: (Incorporated by reference to Exhibit 10.1 the Registrant’s Report on Form 8-K filed on November 23, 2009)
Deferred Compensation Plan.
−Removed: (Incorporated by reference to Exhibit 10.1 the Registrant’s Report on Form 8-K filed on May 28, 2010)
+Added: (Incorporated by reference to Exhibit 4.4 to the Registrant’s Report on Form S-8 filed on May 21, 2021)
Form of Restricted Stock Unit Award Agreement for Executive Officers.
4 unchanged sentences
(Incorporated by reference to Exhibit 10.3 to the Registrant’s Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 3, 2011)
−Removed: Items 15 – 16
−Removed: AND SUBSIDIARIES
Form of Stock Option Grant for Directors.
1 unchanged sentence
Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers.
−Removed: (Incorporated by reference to Appendix A of the Registrant’s Proxy Statement filed October 4, 2012)
+Added: Form of Executive Restricted Stock Unit Award Agreement for Executive Officers.
Amended and Restated Credit Agreement dated as of April 17, 2018, by and among ResMed Inc., as borrower, each of the lenders identified on the Revolving Credit Agreement’s signature pages as a lender, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, joint book runner, swing line lender and l/c issuer, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner.
4 unchanged sentences
(Incorporated by reference to Exhibit 10.3 to the Registrant’s Report on Form 8-K filed on April 19, 2018)
+Added: Items 15 – 16
+Added: AND SUBSIDIARIES
Unconditional Guaranty dated as of April 17, 2018, by each of the guarantors identified on the Term Facility Guaranty’s signature pages as a guarantor, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Term Credit Agreement .
5 unchanged sentences
(Incorporated by reference to Appendix B of ResMed Inc.’s Proxy Statement filed with the Securities and Exchange Commission on October 3, 2018.)
−Removed: Note Purchase Agreement, dated July 10, 2019 among ResMed Inc.
+Added: Note Purchase Agreement, dated July 10, 2019 by and among ResMed Inc.
and the purchasers party to that agreement (including form of 3.24% Series A Senior Note due 2026, form of Series B 3.45% Senior Note due 2029, and form of Subsidiary Guaranty Agreement).
27 unchanged sentences
August 16, 2021
+Added: /S/ HARJIT GILL
+Added: August 16, 2021
/S/ JAN De WITTE
August 16, 2021
+Added: /S/ KAREN DREXLER
+Added: August 16, 2021
+Added: Karen Drexler
/S/ RICHARD SULPIZIO
3 unchanged sentences
August 16, 2021
−Removed: /S/ KAREN DREXLER
−Removed: August 12, 2020
−Removed: Karen Drexler
−Removed: /S/ HARJIT GILL
−Removed: August 12, 2020
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.